PubAg

Main content area

A single dose polyanhydride-based vaccine platform promotes and maintains anti-GnRH antibody titers

Author:
Schaut, Robert G., Brewer, Matthew T., Hostetter, Jesse M., Mendoza, Kriscelle, Vela-Ramirez, Julia E., Kelly, Sean M., Jackman, John K., Dell'Anna, Giuseppe, Howard, Joan M., Narasimhan, Balaji, Zhou, Wen, Jones, Douglas E.
Source:
Vaccine 2018 v.36 no.7 pp. 1016-1023
ISSN:
0264-410X
Subject:
adjuvants, angiogenesis, antibodies, antibody affinity, antigens, estrus, females, gonadotropin-releasing hormone, humoral immunity, immune response, males, mice, ovulation, subcutaneous injection, vaccination, vaccines
Abstract:
Traditionally, vaccination strategies require an initial priming vaccination followed by an antigen boost to generate adequate immunity. Here we describe vaccination against a self-peptide for reproductive sterilization utilizing a three-stage vaccine platform consisting of gonadotropin releasing hormone multiple antigenic peptide (GnRH-MAP) as a soluble injection coupled with subcutaneous administration of polyanhydride-immobilized GnRH-MAP and a cyto-exclusive implant containing GnRH-MAP dendrimer-loaded polyanhydride. This strategy generated and maintained cell-mediated and humoral immunity for up to 41 weeks after a single vaccination in mice with enhanced antibody avidity over time. All intact implants had a grossly visible tissue interface with neovascularization and lymphocytic aggregates. Despite detectable immunity, sterility was not achieved and the immune response did not lead to azoospermia in male mice nor prevent estrus and ovulation in female mice. However, the vaccine delivery device is tunable and the immunogen, adjuvants and release rates can all be modified to enhance immunity. This technology has broad implications for the development of long-term vaccination schemes.
Agid:
6053377